DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Reminyl (Galantamine Hydrobromide) - Summary

 
 



REMINYL SUMMARY

REMINYL® (galantamine hydrobromide) is a reversible, competitive acetylcholinesterase inhibitor.

REMINYL® (galantamine hydrobromide) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.


See all Reminyl indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Reminyl (Galantamine)

Medical News Today: Bone loss may be linked to Alzheimer's disease
Source: Featured Health News from Medical News Today [2016.12.02]
A study in a mouse model of Alzheimer's finds a potential link between early bone loss and degeneration in an area of the brain that makes serotonin.

Bone loss may be linked to Alzheimer's disease
Source: Biology / Biochemistry News From Medical News Today [2016.12.02]
A study in a mouse model of Alzheimer's finds a potential link between early bone loss and degeneration in an area of the brain that makes serotonin.

Benzodiazepine and related drug use increases hip fractures in persons with Alzheimer's disease
Source: Bones / Orthopedics News From Medical News Today [2016.11.25]
The use of benzodiazepines and related drugs increases the risk of hip fracture by 43% in persons with Alzheimer's disease, according to a new study from the University of Eastern Finland.

Alzheimer's disease proteins could be at fault for leading cause of vision loss among older people
Source: Eye Health / Blindness News From Medical News Today [2016.11.22]
Research from the University of Southampton gives new insight into possible causes of Age-related Macular Degeneration (AMD), a leading cause of vision loss among people aged 50 and older.

Alzheimer's disease: New imaging compound may improve earlier diagnosis
Source: Radiology / Nuclear Medicine News From Medical News Today [2016.11.03]
New compound that better identifies amyloid clumps could be used in PET scans to detect early brain changes and track treatment in Alzheimer's disease.

more news >>

Published Studies Related to Reminyl (Galantamine)

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. [2014]
rivastigmine, and memantine for the treatment of AD... CONCLUSIONS: Cholinesterase inhibitors and memantine are able to stabilize or

The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease. [2014]
The prediction of efficacy in long-term treatment of acetylcholinesterase inhibitors (AChEIs) is a major clinical issue, although no consistently strong predictive factors have emerged thus far... Patients who show improvement of episodic memory function during the first 4 weeks of galantamine administration may be likely to particularly benefit from galantamine treatment.

Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. [2011.03]
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer's disease (AD) who would benefit most from long-term galantamine therapy... CONCLUSIONS: Patients who demonstrate improvement, stability, or limited cognitive decline 2-5 months after reaching maintenance doses of galantamine are more likely to experience continued benefit from long-term galantamine therapy.

Galantamine improves sustained attention in chronic cocaine users. [2011.02]
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies.

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. [2011.02]
CONCLUSION: Galantamine showed no ameliorative effects on cognitive measures in this 6month, double-blind study of patients with schizophrenia treated with an assured and stable antipsychotic medication delivery system. Galantamine may not be an appropriate augmentation agent for cognitive impairments in patients with schizophrenia at the dose used. Copyright (c) 2010 Elsevier B.V. All rights reserved.

more studies >>

Clinical Trials Related to Reminyl (Galantamine)

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions [Completed]
The objective of this study was to compare the rate and extent of absorption of Purepac, a subsidiary of Alpharma Inc., U. S.A., galantamine and Janssen Pharmaceutica Products, L. P., U. S.A. (Reminyl),galantamine, administered as a 1 x 4 mg tablet, under fed conditions.

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions [Completed]
The objective of this study was to compare the rate and extent of absorption of Purepac, a subsidiary of Alpharma Inc., U. S.A., galantamine and Janssen Pharmaceutica Products, L. P., U. S.A. (Reminyl),galantamine, administered as a 1 x 4 mg tablet, under fasting conditions.

Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition [Completed]

Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition [Completed]

A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease [Completed]
The purpose of this study is to demonstrate that the change of attention measure is correlated with the changes of caregiver's burden after treatment with galantamine.

more trials >>


Page last updated: 2016-12-02

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015